Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in vivo
Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
Targeting SWI/SNF ATPases in enhancer-addicted human cancers
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders
IRAK4 Modulators for Treatment of Hematologic Malignancies
Novel, potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy
Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
In silico designing of targeted protein degraders
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies | ACS Medicinal Chemistry Letters
Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7
Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313
First in class orally bioavailable BET BRD degraders
Targeting cancer with selective CBP/p300 bromodomain inhibitors
